+

PL2114878T3 - Związki 5-(heterocyklilo)alkilo-N-(arylosulfonylo)indolowe i ich zastosowanie jako ligandy 5-HT6 - Google Patents

Związki 5-(heterocyklilo)alkilo-N-(arylosulfonylo)indolowe i ich zastosowanie jako ligandy 5-HT6

Info

Publication number
PL2114878T3
PL2114878T3 PL07827525T PL07827525T PL2114878T3 PL 2114878 T3 PL2114878 T3 PL 2114878T3 PL 07827525 T PL07827525 T PL 07827525T PL 07827525 T PL07827525 T PL 07827525T PL 2114878 T3 PL2114878 T3 PL 2114878T3
Authority
PL
Poland
Prior art keywords
disorders
compounds
pharmaceutically acceptable
arylsulfonyl
heterocyclyl
Prior art date
Application number
PL07827525T
Other languages
English (en)
Inventor
Nirogi Venkata Satya Ramakrishna
Rama Sastri Kambhampati
Jagadishbabu Konda
Prabhakar Kothmirkar
Venkateswarlu Jasti
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of PL2114878T3 publication Critical patent/PL2114878T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • C07D209/36Oxygen atoms in position 3, e.g. adrenochrome

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
PL07827525T 2007-01-08 2007-07-26 Związki 5-(heterocyklilo)alkilo-N-(arylosulfonylo)indolowe i ich zastosowanie jako ligandy 5-HT6 PL2114878T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN45CH2007 2007-01-08
PCT/IN2007/000312 WO2008084492A1 (en) 2007-01-08 2007-07-26 5-(heterocyclyl)alkyl-n-(arylsulfonyl)indole compounds and their use as 5-ht6 ligands
EP07827525A EP2114878B1 (en) 2007-01-08 2007-07-26 5-(heterocyclyl)alkyl-n-(arylsulfonyl)indole compounds and their use as 5-ht6 ligands

Publications (1)

Publication Number Publication Date
PL2114878T3 true PL2114878T3 (pl) 2011-05-31

Family

ID=39495814

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07827525T PL2114878T3 (pl) 2007-01-08 2007-07-26 Związki 5-(heterocyklilo)alkilo-N-(arylosulfonylo)indolowe i ich zastosowanie jako ligandy 5-HT6

Country Status (23)

Country Link
US (1) US8470830B2 (pl)
EP (1) EP2114878B1 (pl)
JP (1) JP2010515674A (pl)
KR (1) KR101103023B1 (pl)
CN (1) CN101553467B (pl)
AT (1) ATE491685T1 (pl)
AU (1) AU2007343063B2 (pl)
BR (1) BRPI0718737A2 (pl)
CA (1) CA2670717C (pl)
CY (1) CY1111105T1 (pl)
DE (1) DE602007011323D1 (pl)
DK (1) DK2114878T3 (pl)
EA (1) EA017007B1 (pl)
ES (1) ES2357584T3 (pl)
HK (1) HK1132273A1 (pl)
IL (1) IL198821A (pl)
MX (1) MX2009006077A (pl)
NO (1) NO341713B1 (pl)
NZ (1) NZ577769A (pl)
PL (1) PL2114878T3 (pl)
PT (1) PT2114878E (pl)
WO (1) WO2008084492A1 (pl)
ZA (1) ZA200903600B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8318725B2 (en) 2008-09-17 2012-11-27 Suven Life Sciences Limited Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands
CN103304547A (zh) * 2012-03-13 2013-09-18 中国药科大学 一种抗抑郁药维拉唑酮的制备方法
EP3074378A4 (en) * 2013-11-25 2017-05-10 Novogen Ltd. Functionalised and substituted indoles as anti-cancer agents
EP3083588B1 (en) 2013-12-20 2020-12-09 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic compounds and their application in pharmaceuticals
WO2016004882A1 (en) 2014-07-08 2016-01-14 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
MX2017000613A (es) * 2014-07-16 2017-04-27 Novogen ltd Indoles funcionalizados y sustituidos como agentes anticancer.
AU2021305165A1 (en) * 2020-07-06 2023-02-02 Tactogen Inc Advantageous benzothiophene compositions for mental disorders or enhancement

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9026389D0 (en) * 1990-12-05 1991-01-23 Merck Sharp & Dohme Therapeutic agents
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
PL338016A1 (en) 1997-07-11 2000-09-25 Smithkline Beecham Plc Novel chemical compounds
GB9801392D0 (en) 1998-01-22 1998-03-18 Smithkline Beecham Plc Novel compounds
GB9803411D0 (en) 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
CA2370147C (en) 1999-04-21 2009-07-28 Allelix Biopharmaceuticals Inc. Piperidine-indole compounds having 5-ht6 affinity
GB9926302D0 (en) 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
BR0115102B1 (pt) * 2000-11-02 2013-11-26 Compostos 1-aril- ou 1-alquilsulfonil-heterociclilbenzazóis e composição compreendendo os mesmos
ES2272667T3 (es) 2001-01-30 2007-05-01 Eli Lilly And Company Indol-5-il esteres del acido bencenosulfonico como antagonistas de receptor 5-ht6.
BR0207302A (pt) 2001-02-08 2004-02-10 Memory Pharm Corp Trifluorometilpurinas como inibidores da fosfodiesterase 4
CA2449874C (en) 2001-06-07 2009-06-23 F. Hoffmann-La Roche Ag New indole derivatives with 5-ht6 receptor affinity
US20040242589A1 (en) * 2001-08-07 2004-12-02 Bromidge Steven Mark 3-arylsulfonyl-7-piperzinyl-indoles-benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders
WO2003065046A2 (en) 2002-02-01 2003-08-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor
US20070270432A1 (en) 2002-02-05 2007-11-22 James Hagan Novel Method
EP1956004B1 (en) 2002-03-27 2012-06-13 Glaxo Group Limited Quinoline derivatives and their use as 5-HT6 ligands
JP4559230B2 (ja) * 2002-11-28 2010-10-06 スベン ライフ サイエンシズ リミティド セロトニン受容体に対する親和性を有する新規n−アリールスルホニル−3−置換されたインドール、その調製方法、それを含有する医薬組成物
WO2004048328A2 (en) 2002-11-28 2004-06-10 Suven Life Sciences Limited N-arylsulfonyl-3-aminoalkoxyindoles
AU2003292508A1 (en) 2002-11-28 2004-06-18 Suven Life Sciences Limited N-arylalkyl-3-aminoalkoxyindoles and their use as 5-ht ligands
ATE355292T1 (de) 2002-12-18 2006-03-15 Suven Life Sciences Ltd Tetrazyklische 3-substituierte indole mit serotoninrezeptoraffinität
WO2004108671A1 (en) * 2003-06-06 2004-12-16 Suven Life Sciences Limited Substituted indoles with serotonin receptor affinity, process for their preparation and pharmaceutical compositions containing them
ES2222828B1 (es) * 2003-07-30 2006-04-16 Laboratorios Del Dr. Esteve, S.A. Derivados de 1-sulfonilindoles, su preparacion y su aplicacion como medicamentos.
SI1919896T1 (sl) 2005-08-12 2010-04-30 Suven Life Sciences Ltd Aminoaril sulfonamidni derivati kot funkcionalni 5-HT6 ligandi
BRPI0712898A2 (pt) * 2006-07-03 2013-01-08 Biovitrum Ab indàis como moduladores de 5-ht6

Also Published As

Publication number Publication date
CY1111105T1 (el) 2015-06-11
US20100041673A1 (en) 2010-02-18
BRPI0718737A2 (pt) 2014-03-25
EA017007B1 (ru) 2012-09-28
CN101553467A (zh) 2009-10-07
AU2007343063A1 (en) 2008-07-17
CA2670717C (en) 2012-01-10
ES2357584T3 (es) 2011-04-27
KR101103023B1 (ko) 2012-01-05
NO20092067L (no) 2009-09-04
HK1132273A1 (pl) 2010-02-19
NZ577769A (en) 2011-01-28
US8470830B2 (en) 2013-06-25
EA200970675A1 (ru) 2009-12-30
ZA200903600B (en) 2010-07-28
AU2007343063A8 (en) 2009-07-23
IL198821A0 (en) 2010-02-17
EP2114878A1 (en) 2009-11-11
KR20090080544A (ko) 2009-07-24
IL198821A (en) 2014-11-30
ATE491685T1 (de) 2011-01-15
WO2008084492A1 (en) 2008-07-17
CN101553467B (zh) 2011-12-07
NO341713B1 (no) 2018-01-08
AU2007343063B2 (en) 2011-02-17
PT2114878E (pt) 2011-03-10
CA2670717A1 (en) 2008-07-17
EP2114878B1 (en) 2010-12-15
DE602007011323D1 (de) 2011-01-27
MX2009006077A (es) 2009-06-17
JP2010515674A (ja) 2010-05-13
DK2114878T3 (da) 2011-03-14

Similar Documents

Publication Publication Date Title
ZA200903600B (en) 5-(Heterocyclyl)alkyl-N-(arylsulfonyl)indole compounds and their use as 5-HT6 ligands
MY167135A (en) Fused heterocyclic derivatives and methods of use
MX2010007683A (es) Derivados heterociclicos fusionados y metodos de uso como inhibidores de c-met.
MX2009000900A (es) Derivados de imidazolonas sustituidas, preparacion y usos.
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
MY147890A (en) 9-(pyrazol-3-yl)-9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidaz0 [4,5-b] pyridin-5-amine derivatives and their use for the treatment of cancer
UA104988C2 (uk) Похідні піроніндолу та спосіб їх отримання
MY147677A (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
HK1138264A1 (en) Aminoalkoxy aryl sulfonamide compounds and their use as 5-ht6 ligands
MX2009006757A (es) Compuestos de 4-(heterociclil)alquil-n-(arilsulfonil) indol y su uso como ligandos de la 5-hidroxitriptamina6.
MX2007006387A (es) Derivados de piridina 3-substituidos como antagonistas h3.
HRP20110780T1 (en) Amino arylsulfonamide compounds and their use as 5-ht6 ligands field of invention
MX2013001988A (es) Compuestos de heterociclilo comoligandos del receptor h3 de la histamina
PL1732902T3 (pl) Pochodne nukleozydów i ich terapeutyczne zastosowanie
点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载